Retatrutide vs Gonadorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Gonadorelin
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH). It stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), supporting natural hormone production.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Gonadorelin |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Binds to GnRH receptors in the pituitary gland, triggering pulsatile release of LH and FSH. This stimulates testicular or ovarian function and natural sex hormone production. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Men: 100-200mcg subcutaneously 2-3 times daily. Women (fertility): Per clinical protocol. HRT support: Often combined with other therapies. |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Subcutaneous injection. Pulsatile administration mimics natural GnRH release patterns. Often used during or after testosterone therapy. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Headache, flushing, injection site reactions. In women may cause ovarian hyperstimulation. Generally well-tolerated. |
| Best For |